Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.achillestx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/5/2024 | $8.00 → $2.00 | Overweight → Neutral | Piper Sandler |
Piper Sandler downgraded Achilles Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously
LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022. James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals
LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities. Bernhard is a veteran biotechnology and pharmaceutical executive with more than three decades in senior leadership roles. He most recently served as CEO of Biotest AG in Germany and also served as chairman of the board of directors at Symphogen A/S, Denmark until its acquisition by Servier SA in June 2
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). "We are very pleased to welcome leading experts Dr. Gros and Dr. Creelan to our Scientific Advisory Board. With two ongoing clinical trials, CHIRON in non-small cell lung cancer (NSCLC) and THETIS in melanoma, their extensive research experience and deep clinical expertise with cell-based immunotherapies for the treatment of solid tumors will be invaluable as we continue to advance the clinic
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
S-8 - Achilles Therapeutics plc (0001830749) (Filer)
20-F - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
6-K - Achilles Therapeutics plc (0001830749) (Filer)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13D/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13D/A - Achilles Therapeutics plc (0001830749) (Subject)
SC 13D/A - Achilles Therapeutics plc (0001830749) (Subject)
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023,
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "We are pleased with progr
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell responses - - Strong cash position of $144 million supports operations through 2025 - LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended June 30, 2023, and recent business highlights. "W
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5 million supports operations into mid-2025 - LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2023, and recent business highlights. "We continue to make progress in our ongoing Phase I/IIa clinical trials evaluating our clonal neoantigen-rea
- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients - - Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens - - Strong cash position of $173.3 million supports operations into mid-2025 - LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights. "In 2022, we were plea
- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability profile potentially expands opportunity to include patients ineligible for high dose lymphodepletion or high dose IL-2 - - Mechanism of action informed by translational science platform's capability to correlate cNeT with anti-tumor activity - - Additional monotherapy data and initial anti-PD-1 combination data expected in 2023 - - Conference call and webcast today at 8:00am ET / 1:00pm UK - LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable responses in NSCLC with cNeT and reduced-dose lymphodepletion and IL-2 - - Company to host a conference call and webcast on December 6, 2022 at 8:00am ET / 1:00pm UK - LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that an abstract highlighting
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9 million supports all planned operations into Q2 2025 - LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and recent business highlights. "This quarter we continued to advance our clinical programs and look forward to providing an update from our
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t
Combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal
LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company's American Depositary Shares (the "ADS") on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023,
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNe
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360)Speaker: Sergio Quezada, PhD, Chief Scientific OfficerPresentation: Targeting Clonal Neoantigens with Precision Cell TherapiesLocation: New York Marriott at The Brooklyn Bridge, Brooklyn NY Date: February 29, 2024Time: 10:30am ET For more information about IO360, please visit https://io360summit.com. About Achilles Therapeutics
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced publication of a ‘Comment' in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward. The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction, makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "We are pleased with progr
NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.However, such scenarios can present compelling investment opportunities. Companies trading below their cash value, especially those gearing up for strategic shifts or innovative ventur
Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target from $11 to $6.
Piper Sandler analyst Joseph Catanzaro downgrades Achilles Therapeutics (NASDAQ:ACHL) from Overweight to Neutral and lowers the price target from $8 to $2.
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03. Check This Out: Insiders Buying Walgreens And 2 Other Stocks Leading and Lagging Sectors Communication services shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares rose by just 0.1%. Top Headline Shares of RPM International Inc. (NYSE:RPM) fell more than 5% on Thursday after the company reported third-quarter FY24 results. Sales rose 0.4% Y/Y to $1.523 billion, slightly beating the consensus of $1
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ:ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock w
Gainers Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. Macrogenics (NASDAQ:MGNX) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. Curis (NASDAQ
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72. Check This Out: Insiders Buying Walgreens And 2 Other Stocks Leading and Lagging Sectors Real estate shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares rose by just 0.01%. Top Headline ConAgra Brands Inc (NYSE:CAG) reported better-than-expected third-quarter financial results. ConAgra reported a third-quarter FY24 sales decline of 1.7% year-on-year to $3.03 billion, beating the analyst consensus estimate
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ:CADL) shares rose 27.97% to $2.15. The company's market cap stands at $63.0 million. Healthcare Triangle (NASDAQ:HCTI) stock rose 23.56% to $2.36. The company's market cap stands at $10.9 million. SINTX Techs (NASDAQ:SINT) stock increased by 19.56% to $0.03. The market value of their outstanding shares is at $1.4 million. Addex Therapeutics (NASDAQ:ADXN) shares increased by 16.84% to $18.0. The company's market cap stands at $19.0 million. Novo Integrated Sciences (NASDAQ:NVOS) shares mo
Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.14) by 228.57 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same period last year.